Press Release Biocartis Group NV: Biocartis announces H1 202

PRESS RELEASE: INSIDE INFORMATION / REGULATED INFORMATION 26 September 2023, 07:00 CEST BIOCARTIS ANNOUNCES H1 2023 RESULTS AND PROVIDES AN UPDATE ON THE OPERATIONAL REORGANIZATION AND RECAPITALIZATION Company will host a conference call with live webcast presentation today at 14:30 CEST / 13:30 BST (UK) / 08:30 EDT (US) to discuss H1 2023 results Solid performance with 22% growth of oncology cartridge revenue, a 40% gross margin on product sales and a 20% improvement in EBITDA to EUR -14.5mOper

Related Keywords

United Kingdom , Japan , United States , Mechelen , Region Flamande , Belgium , Belgian , Japanese , America , Skylinedx Merlin , Herman Verrelst , Nichirei Biosciences , Jean Marc Roelandt , Piet Houwen , Roger Moody , Nico Houthaeve , George Cardoza , Deloitte Bedrijfsrevisoren Reviseurs , Exchange Commission , Shareholders Of Biocartis Group , Corporate Communications Investor Relations Biocartis , Head Of Service Delivery , Biocartis Us Inc , Assay Technologies Ltd , Neither The Company , Biocartis Group , Drug Administration , Twitter , Company Or Biocartis , Bonds , Ministry Of Health , European Union , Euronext Brussels , Interim Financial Reporting , Chief Executive Officer , Balance Sheet Restructuring , New Biocartis , Second Ranking Secured Convertible Bonds , Equity Injection , Service Delivery , Medical Advisory Board , Assay Kit , Breast Cancer Subtyping , Thyroidprint Assay , Polymerase Chain Reaction , United States Securities , Biocartis Group Nv , Secured Creditors , Operational Performance ,